_id
6915ef68bc934aba376b1f3b
Ticker
RKVTF
Name
RKVTF
Exchange
PINK
Address
999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.rakovinatherapeutics.com
Description
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Last Close
0.0761
Volume
500
Current Price
0.0828
Change
0.0002
Last Updated
2026-01-06T10:19:25.751Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
1609365
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
1641545
Operating Income
-1641545
Interest Expense
139752
Pretax Income
-1781757
Net Income
-1781757
Eps
-0.08425164148789398
Dividends Per Share
-
Shares Outstanding
21148039
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-460
Cash
822293
Short Term Investments
-
Receivables
153367
Inventories
-
Total Current Assets
1691216
Property Plant Equipment
-
Total Assets
5267709
Payables
684456
Short Term Debt
-
Long Term Debt
1159023
Total Liabilities
3380018
Equity
1887691
Bs_currency_symbol
CAD
Depreciation
135129
Change In Working Capital
74825
Cash From Operations
-1035199
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-25393
Net Change In Cash
-1060592
Cf_currency_symbol
CAD
PE
-
PB
0.9276187835826945
ROE
-94.38817052155251
ROA
-33.8241349322827
FCF
-1035199
Fcf Percent
-
Piotroski FScore
1
Health Score
32
Deep Value Investing Score
4.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
2.8
Garp Investing Score
1
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
1.5
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
1641545
Quarters > 0 > income Statement > operating Income
-1641545
Quarters > 0 > income Statement > interest Expense
139752
Quarters > 0 > income Statement > pretax Income
-1781757
Quarters > 0 > income Statement > net Income
-1781757
Quarters > 0 > income Statement > eps
-0.08425164148789398
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
21148039
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-460
Quarters > 0 > income Statement > currency_symbol
CAD
Quarters > 0 > balance Sheet > cash
822293
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
153367
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1691216
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
5267709
Quarters > 0 > balance Sheet > payables
684456
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
1159023
Quarters > 0 > balance Sheet > total Liabilities
3380018
Quarters > 0 > balance Sheet > equity
1887691
Quarters > 0 > balance Sheet > currency_symbol
CAD
Quarters > 0 > cash Flow > net Income
-1781757
Quarters > 0 > cash Flow > depreciation
135129
Quarters > 0 > cash Flow > change In Working Capital
74825
Quarters > 0 > cash Flow > cash From Operations
-1035199
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-25393
Quarters > 0 > cash Flow > net Change In Cash
-1060592
Quarters > 0 > cash Flow > currency_symbol
CAD
Quarters > 0 > ratios > PE
-0.08425164148789398
Quarters > 0 > ratios > PB
0.9276187835826945
Quarters > 0 > ratios > ROE
-94.38817052155251
Quarters > 0 > ratios > ROA
-33.8241349322827
Quarters > 0 > ratios > FCF
-1035199
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
32
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
2825474
Quarters > 1 > income Statement > operating Income
-2825474
Quarters > 1 > income Statement > interest Expense
91688
Quarters > 1 > income Statement > pretax Income
-2916944
Quarters > 1 > income Statement > net Income
-2916944
Quarters > 1 > income Statement > eps
-0.1379297626602637
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
21148039
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
218
Quarters > 1 > income Statement > currency_symbol
CAD
Quarters > 1 > balance Sheet > cash
1882886
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
117402
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
2842498
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
6554120
Quarters > 1 > balance Sheet > payables
758669
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
1118463
Quarters > 1 > balance Sheet > total Liabilities
3338110
Quarters > 1 > balance Sheet > equity
3216010
Quarters > 1 > balance Sheet > currency_symbol
CAD
Quarters > 1 > cash Flow > net Income
-2916944
Quarters > 1 > cash Flow > depreciation
133660
Quarters > 1 > cash Flow > change In Working Capital
-302341
Quarters > 1 > cash Flow > cash From Operations
-3028440
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
1807067
Quarters > 1 > cash Flow > currency_symbol
CAD
Quarters > 1 > ratios > PE
-0.1379297626602637
Quarters > 1 > ratios > PB
0.5444814006175355
Quarters > 1 > ratios > ROE
-90.7007129952954
Quarters > 1 > ratios > ROA
-44.50550188278518
Quarters > 1 > ratios > FCF
-3028440
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
2110346
Quarters > 2 > income Statement > operating Income
-2110346
Quarters > 2 > income Statement > interest Expense
66779
Quarters > 2 > income Statement > pretax Income
-2179823
Quarters > 2 > income Statement > net Income
-2179823
Quarters > 2 > income Statement > eps
-0.15482514453710164
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
14079257
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-2698
Quarters > 2 > income Statement > currency_symbol
CAD
Quarters > 2 > balance Sheet > cash
75819
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
59495
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
932864
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
4778146
Quarters > 2 > balance Sheet > payables
871075
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2386379
Quarters > 2 > balance Sheet > equity
2391767
Quarters > 2 > balance Sheet > currency_symbol
CAD
Quarters > 2 > cash Flow > net Income
-2179823
Quarters > 2 > cash Flow > depreciation
132191
Quarters > 2 > cash Flow > change In Working Capital
570354
Quarters > 2 > cash Flow > cash From Operations
-1236924
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-1236924
Quarters > 2 > cash Flow > currency_symbol
CAD
Quarters > 2 > ratios > PE
-0.15482514453710164
Quarters > 2 > ratios > PB
0.48740637344691184
Quarters > 2 > ratios > ROE
-91.13860171162158
Quarters > 2 > ratios > ROA
-45.620686349893866
Quarters > 2 > ratios > FCF
-1236924
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
1394801
Quarters > 3 > income Statement > operating Income
-1394801
Quarters > 3 > income Statement > interest Expense
69084
Quarters > 3 > income Statement > pretax Income
-1483988
Quarters > 3 > income Statement > net Income
-1483988
Quarters > 3 > income Statement > eps
-0.1056275075614319
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
14049257
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-20103
Quarters > 3 > income Statement > currency_symbol
CAD
Quarters > 3 > balance Sheet > cash
1312743
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
81334
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
2263447
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
6240920
Quarters > 3 > balance Sheet > payables
420811
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1942005
Quarters > 3 > balance Sheet > equity
4298915
Quarters > 3 > balance Sheet > currency_symbol
CAD
Quarters > 3 > cash Flow > net Income
-1483988
Quarters > 3 > cash Flow > depreciation
135129
Quarters > 3 > cash Flow > change In Working Capital
-489431
Quarters > 3 > cash Flow > cash From Operations
-1759689
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
2817383
Quarters > 3 > cash Flow > net Change In Cash
1057694
Quarters > 3 > cash Flow > currency_symbol
CAD
Quarters > 3 > ratios > PE
-0.1056275075614319
Quarters > 3 > ratios > PB
0.2705981578142391
Quarters > 3 > ratios > ROE
-34.52005913119938
Quarters > 3 > ratios > ROA
-23.778353191516636
Quarters > 3 > ratios > FCF
-1759689
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
41
Annuals > 0 > quarter
2024-09-30
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
3788051
Annuals > 0 > income Statement > operating Income
-3788051
Annuals > 0 > income Statement > interest Expense
268540
Annuals > 0 > income Statement > pretax Income
-4072618
Annuals > 0 > income Statement > net Income
-4072618
Annuals > 0 > income Statement > eps
-0.04510638180047608
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
90289175
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-21846
Annuals > 0 > income Statement > currency_symbol
CAD
Annuals > 0 > balance Sheet > cash
1312743
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
81334
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
2263447
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
6240920
Annuals > 0 > balance Sheet > payables
420811
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
1942005
Annuals > 0 > balance Sheet > equity
4298915
Annuals > 0 > balance Sheet > currency_symbol
CAD
Annuals > 0 > cash Flow > net Income
-4072618
Annuals > 0 > cash Flow > depreciation
537578
Annuals > 0 > cash Flow > change In Working Capital
-550874
Annuals > 0 > cash Flow > cash From Operations
-3855137
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
4731567
Annuals > 0 > cash Flow > net Change In Cash
876430
Annuals > 0 > cash Flow > currency_symbol
CAD
Annuals > 0 > ratios > PE
-0.04510638180047608
Annuals > 0 > ratios > PB
1.598311717607815
Annuals > 0 > ratios > ROE
-94.73595081549647
Annuals > 0 > ratios > ROA
-65.25669292347924
Annuals > 0 > ratios > FCF
-3855137
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-09-30
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
2482100
Annuals > 1 > income Statement > operating Income
-2482100
Annuals > 1 > income Statement > interest Expense
151309
Annuals > 1 > income Statement > pretax Income
-2612924
Annuals > 1 > income Statement > net Income
-2612925
Annuals > 1 > income Statement > eps
-0.03728226861910746
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
70084925
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-1885
Annuals > 1 > income Statement > currency_symbol
CAD
Annuals > 1 > balance Sheet > cash
436313
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
20079
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
632528
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
5147579
Annuals > 1 > balance Sheet > payables
80358
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
1333096
Annuals > 1 > balance Sheet > total Liabilities
1487743
Annuals > 1 > balance Sheet > equity
3659836
Annuals > 1 > balance Sheet > currency_symbol
CAD
Annuals > 1 > cash Flow > net Income
-1787910
Annuals > 1 > cash Flow > depreciation
536109
Annuals > 1 > cash Flow > change In Working Capital
24154
Annuals > 1 > cash Flow > cash From Operations
-1861711
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
1401193
Annuals > 1 > cash Flow > net Change In Cash
-460518
Annuals > 1 > cash Flow > currency_symbol
CAD
Annuals > 1 > ratios > PE
-0.03728226861910746
Annuals > 1 > ratios > PB
1.4572955707578152
Annuals > 1 > ratios > ROE
-71.39459254458397
Annuals > 1 > ratios > ROA
-50.760270022082224
Annuals > 1 > ratios > FCF
-1861711
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-09-30
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
2817479
Annuals > 2 > income Statement > operating Income
-2817479
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-2791234
Annuals > 2 > income Statement > net Income
-2791234
Annuals > 2 > income Statement > eps
-0.039972132121810985
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
69829500
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-2030
Annuals > 2 > income Statement > currency_symbol
CAD
Annuals > 2 > balance Sheet > cash
896831
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
14883
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
1069601
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
6120761
Annuals > 2 > balance Sheet > payables
27739
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
107048
Annuals > 2 > balance Sheet > equity
6013713
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-2791234
Annuals > 2 > cash Flow > depreciation
536109
Annuals > 2 > cash Flow > change In Working Capital
79731
Annuals > 2 > cash Flow > cash From Operations
-1916860
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
2150
Annuals > 2 > cash Flow > net Change In Cash
-1914710
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.039972132121810985
Annuals > 2 > ratios > PB
0.8836512400907726
Annuals > 2 > ratios > ROE
-46.41448635809524
Annuals > 2 > ratios > ROA
-45.60272815749545
Annuals > 2 > ratios > FCF
-1916860
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-09-30
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
2474330
Annuals > 3 > income Statement > operating Income
-2474330
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-5521139
Annuals > 3 > income Statement > net Income
-5521139
Annuals > 3 > income Statement > eps
-0.07909034781113912
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
69808000
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-3055348
Annuals > 3 > income Statement > currency_symbol
CAD
Annuals > 3 > balance Sheet > cash
2811541
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
74025
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
3070973
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
8658242
Annuals > 3 > balance Sheet > payables
39664
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
113979
Annuals > 3 > balance Sheet > equity
8544263
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-5521139
Annuals > 3 > cash Flow > depreciation
412731
Annuals > 3 > cash Flow > change In Working Capital
-145473
Annuals > 3 > cash Flow > cash From Operations
-2308183
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
4319717
Annuals > 3 > cash Flow > net Change In Cash
2811534
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.07909034781113912
Annuals > 3 > ratios > PB
0.6217492134780963
Annuals > 3 > ratios > ROE
-64.61808350234539
Annuals > 3 > ratios > ROA
-63.76743685380936
Annuals > 3 > ratios > FCF
-2308183
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.08425164148789398
Valuation > metrics > PB
0.9276187835826945
Valuation > final Score
70
Valuation > verdict
7.2% Undervalued
Profitability > metrics > ROE
-94.38817052155251
Profitability > metrics > ROA
-105.35360356098806
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.7905568231241236
Risk > metrics > Interest Coverage
-11.746128856832103
Risk > final Score
-17
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.4708907511951095
Liquidity > metrics > Quick Ratio
2.4708907511951095
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-93
Prev Risks > 1
-78
Prev Risks > 2
-21
Prev Liquidities > 0
100
Prev Liquidities > 1
77
Prev Liquidities > 2
100
Updated At
2026-01-20T22:29:32.360Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-28
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-05-28
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
-0.0108
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2024-12-31
Earnings History > 2 > report Date
2024-12-31
Earnings History > 2 > date
2024-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.106
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-09-30
Earnings History > 3 > report Date
2024-11-25
Earnings History > 3 > date
2024-09-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.0083
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-06-30
Earnings History > 4 > report Date
2024-08-30
Earnings History > 4 > date
2024-06-30
Earnings History > 4 > before After Market
AfterMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.0085
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AWhen Will Rakovina Therapeutics Inc. (CVE:RKV) Turn A Profit? Yahoo Finance
Read more →(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of RKVTF
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
—
Date
2025-03-31
EPS Actual
-0.0108
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.